Study of Ruxolitinib Cream in Children With Atopic Dermatitis
A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Sponsor: Incyte Corporation
This PHASE1 trial investigates Atopic Dermatitis and is currently completed. Incyte Corporation leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
- Innovaderm Research
For direct contact, visit the study record on ClinicalTrials.gov .